Contributors |
|
v | |
Acknowledgments |
|
xix | |
Preface |
|
xxi | |
|
Chapter 1 Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide |
|
|
1 | (98) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 | (9) |
|
1.1 Blood-brain barrier leakage in AD patients |
|
|
4 | (2) |
|
1.2 Blood-borne factors influence AD brain pathology |
|
|
6 | (2) |
|
1.3 Specificity of amyloid beta peptide deposition in AD brain |
|
|
8 | (2) |
|
1.4 Mesenchymal stem cells and AD brain pathology |
|
|
10 | (1) |
|
2 Neurotrophic factors in AD |
|
|
11 | (3) |
|
2.1 Neurotrophic factors changes in human brain with AD |
|
|
12 | (1) |
|
2.2 Serotonin and oxidative stress in AD |
|
|
13 | (1) |
|
2.3 Antibodies to A0P is neuroprotective in AD |
|
|
13 | (1) |
|
3 Our observation of nanowired delivery of agents in AD |
|
|
14 | (7) |
|
3.1 Methodological consideration |
|
|
14 | (1) |
|
3.2 Alzheimer's disease model |
|
|
15 | (1) |
|
3.3 Concussive head injury |
|
|
16 | (1) |
|
3.4 Treatment strategies in AD |
|
|
16 | (2) |
|
|
18 | (3) |
|
3.6 Biochemical measurement |
|
|
21 | (1) |
|
|
21 | (24) |
|
4.1 Rat model of AD induced by ABP infusion |
|
|
21 | (3) |
|
4.2 Blood-brain bajrier breakdown in AD |
|
|
24 | (4) |
|
4.3 Brain edema formation in ABP infusion induced AD |
|
|
28 | (3) |
|
4.4 Brain pathology in A0P infusion induced AD |
|
|
31 | (10) |
|
4.5 Ultrastructural brain pathology in AD induced by ApP infusion |
|
|
41 | (2) |
|
4.6 Biochemical changes in ApP infusion induced AD model |
|
|
43 | (1) |
|
4.7 Concussive head injury exacerbated biochemical changes in CSF of ApP infusion induced AD |
|
|
44 | (1) |
|
5 Neuroprotective strategies in AD induced by ApP infusion |
|
|
45 | (11) |
|
5.1 Nanowired cerebrolysin with MSCs and ApPmAb reduces blood-brain barrier breakdown |
|
|
46 | (1) |
|
5.2 Nanowired cerebrolysin with MSCs and ApPmAb reduces brain edema formation |
|
|
47 | (2) |
|
5.3 Nanowired cerebrolysin with MSCs and ApPmAb reduces brain pathology |
|
|
49 | (6) |
|
5.4 Nanowired cerebrolysin with MSCs and ApPmAb reduces biochemical changes in CSF |
|
|
55 | (1) |
|
|
56 | (4) |
|
7 Conclusion and future perspectives |
|
|
60 | (39) |
|
|
61 | (1) |
|
|
61 | (1) |
|
|
62 | (37) |
|
Chapter 2 Glioblastoma: What can we do for these patients today and what will we be able to do in the future? |
|
|
99 | (20) |
|
|
|
|
|
|
|
|
100 | (1) |
|
2 Modem approach to GBM treatment |
|
|
100 | (3) |
|
|
103 | (1) |
|
4 Interaction of stem cells and cancer cells |
|
|
104 | (3) |
|
|
107 | (1) |
|
6 TGFp and targeted therapy |
|
|
108 | (1) |
|
7 Wnt-inhibitors in GBM treatment |
|
|
109 | (1) |
|
8 Nanotechnologies, cerebral edema and blood-brain barrier |
|
|
110 | (3) |
|
|
113 | (6) |
|
|
114 | (5) |
|
Chapter 3 Network pharmacological mechanism of Cinobufotalin against glioma |
|
|
119 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
120 | (1) |
|
|
121 | (1) |
|
2.1 Compounds of Cinobufotalin and screening of related targets of Cinobufotalin |
|
|
121 | (1) |
|
2.2 Target network map of Cinobufotalin |
|
|
121 | (1) |
|
2.3 GO biological process and KEGG metabolic pathway of Cinobufotalin |
|
|
122 | (1) |
|
2.4 Prediction target genes of glioma |
|
|
122 | (1) |
|
|
122 | (10) |
|
3.1 Main active components and prediction targets of Cinobufotalin |
|
|
122 | (1) |
|
3.2 Analysis results of GO biological process and KEGG metabolic pathway |
|
|
122 | (4) |
|
3.3 Protein-protein interaction (PPI) network construction of Cinobufotalin |
|
|
126 | (1) |
|
3.4 Prediction of targets between Cinobufotalin and glioma |
|
|
126 | (3) |
|
3.5 KEGG pathway enrichment analysis between Cinobufotalin and glioma |
|
|
129 | (3) |
|
|
132 | (7) |
|
|
135 | (1) |
|
|
135 | (4) |
|
Chapter 4 Nanodelivery of oxiracetam enhances memory, functional recovery and induces neuroprotection following concussive head injury |
|
|
139 | (92) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
140 | (3) |
|
1.1 Dementia and neurodegeneration |
|
|
142 | (1) |
|
|
143 | (1) |
|
3 Molecular mechanisms associated with neurodegenerative diseases |
|
|
144 | (2) |
|
3.1 Amyloid precursor protein |
|
|
144 | (1) |
|
|
145 | (1) |
|
|
145 | (1) |
|
4 Traumatic brain injury induces Alzheimer's disease |
|
|
146 | (1) |
|
5 Inflammation and oxidative stress following neurodegenerative diseases |
|
|
147 | (2) |
|
6 Oxiracetam and brain function |
|
|
149 | (2) |
|
7 Nanodelivery of drug for neurological dysfunctions |
|
|
151 | (3) |
|
7.1 Materials and methods |
|
|
152 | (2) |
|
8 Nanoformulation of oxiracetam |
|
|
154 | (8) |
|
|
154 | (1) |
|
|
155 | (1) |
|
|
155 | (7) |
|
|
162 | (35) |
|
9.1 Nanowired oxiracetam characterization |
|
|
162 | (1) |
|
9.2 Oxiracetam and physiological variables in concussive head injury |
|
|
162 | (4) |
|
9.3 Oxiracetam and the blood-brain barrier in CHI |
|
|
166 | (2) |
|
9.4 Oxiracetam and cerebral blood flow in CHI |
|
|
168 | (1) |
|
9.5 Oxiracetam and brain edema formation in CHI |
|
|
169 | (2) |
|
9.6 Oxiracetam influences regional brain functions |
|
|
171 | (8) |
|
9.7 Oxiracetam influence biobehavioral changes in CHI |
|
|
179 | (3) |
|
9.8 Oxiracetam influences biochemical changes in CSF following CHI |
|
|
182 | (2) |
|
9.9 Oxiracetam and brain pathology |
|
|
184 | (13) |
|
|
197 | (5) |
|
|
202 | (1) |
|
|
202 | (29) |
|
|
202 | (1) |
|
|
203 | (1) |
|
|
203 | (28) |
|
Chapter 5 Clinical neurorestorative cell therapies for stroke |
|
|
231 | (18) |
|
|
|
|
|
|
231 | (1) |
|
2 Basic information of cell therapies |
|
|
232 | (1) |
|
3 Results of exploring trials or studies |
|
|
233 | (3) |
|
|
233 | (1) |
|
3.2 Mononuclear cells (MNCs) |
|
|
234 | (1) |
|
3.3 Mesenchymal stromal cells (MSCs) |
|
|
235 | (1) |
|
3.4 Olfactory ensheathing cells (OECs) |
|
|
235 | (1) |
|
3.5 Hemopoietic stem cells (HSTs) |
|
|
236 | (1) |
|
3.6 Mesenchymal stem cell products |
|
|
236 | (1) |
|
3.7 Neural stem cell products |
|
|
236 | (1) |
|
3.8 Combination cell therapy |
|
|
236 | (1) |
|
4 Results of multicenter, double-blind or observing-blind, randomized, placebo-controlled trials |
|
|
236 | (3) |
|
|
239 | (1) |
|
|
240 | (9) |
|
|
240 | (1) |
|
|
241 | (8) |
|
Chapter 6 Nanodelivery of traditional Chinese Gingko Biloba extract EGb-761 and bilobalide BN-52021 induces superior neuroprotective effects on pathophysiology of heat stroke |
|
|
249 | (68) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
250 | (4) |
|
1.1 Heat stress and heat wave induced mortality |
|
|
252 | (1) |
|
1.2 Heat shock proteins (HSPs) synthesis in heat stress |
|
|
253 | (1) |
|
2 Neurological dysfunction in hyperthermia |
|
|
254 | (2) |
|
2.1 Hyperthermia and cell signaling |
|
|
255 | (1) |
|
3 Cytokines release in hyperthermia |
|
|
256 | (6) |
|
3.1 Amino acid Neurotransmitters in hyperthermia |
|
|
256 | (1) |
|
3.2 Blood-brain barrier damage in hyperthermia |
|
|
256 | (1) |
|
3.3 Cerebral blood flow and metabolism disruption in hyperthermia |
|
|
257 | (1) |
|
3.4 Oxidative stress and brain pathology in hyperthermia |
|
|
258 | (1) |
|
3.5 Chinese traditional medicine extract of Gingko Biloba (EGb-761) |
|
|
259 | (1) |
|
3.6 Nanowires drug delivery to CNS |
|
|
260 | (2) |
|
4 Our observations on EGb-761 and BN-52021 on heat stress induced brain pathology |
|
|
262 | (1) |
|
5 Nanowired preparation of Gingko biloba extract |
|
|
262 | (2) |
|
|
262 | (1) |
|
5.2 Fabrication of titanate nanowires |
|
|
263 | (1) |
|
|
263 | (1) |
|
5.4 Drug loading and delivery |
|
|
264 | (1) |
|
6 Heat Stress Model of hyperthermic brain injury |
|
|
264 | (1) |
|
|
264 | (1) |
|
6.2 Exposure to heat stress |
|
|
264 | (1) |
|
|
264 | (2) |
|
8 Physiological parameters |
|
|
266 | (1) |
|
9 Pathophysiological parameters |
|
|
267 | (4) |
|
|
271 | (1) |
|
11 Our findings in heat stress |
|
|
271 | (1) |
|
|
271 | (1) |
|
|
272 | (1) |
|
13 Physiological variables |
|
|
272 | (2) |
|
14 Blood-brain barrier permeability |
|
|
274 | (1) |
|
|
274 | (3) |
|
16 Brain edema formation and volume swelling |
|
|
277 | (3) |
|
17 Brain pathology after heat exposure |
|
|
280 | (1) |
|
18 EGb-761 treatment on heat exposure induced pathophysiology |
|
|
280 | (4) |
|
19 BN-52021 treatment on heat exposure induced pathophysiology |
|
|
284 | (1) |
|
20 NWEGb-761 treatment on chronic heat stressed induced pathophysiology |
|
|
285 | (2) |
|
21 NWBN-52021 treatment on chronic heat stressed induced pathophysiology |
|
|
287 | (1) |
|
|
288 | (2) |
|
23 Conclusion and future perspectives |
|
|
290 | (27) |
|
|
291 | (1) |
|
|
291 | (1) |
|
|
291 | (26) |
|
Chapter 7 Upregulation of hemeoxygenase enzymes H0-1 and HO-2 following ischemia-reperfusion injury in connection with experimental cardiac arrest and cardiopulmonary resuscitation: Neuroprotective effects of methylene blue |
|
|
317 | (60) |
|
|
|
|
|
|
|
|
|
|
|
|
318 | (1) |
|
2 Cerebral ischemia and reperfusion |
|
|
319 | (2) |
|
3 Mechanisms of neuronal cell death following ischemia/reperfusion |
|
|
321 | (3) |
|
3.1 Caspase dependent cell death |
|
|
321 | (1) |
|
3.2 Caspase independent cell death |
|
|
322 | (1) |
|
3.3 Free radical production following cerebral ischemia |
|
|
322 | (2) |
|
4 Hemeoxygenase enzymes HO-1 and HO-2 following ischemia-reperfusion injury |
|
|
324 | (5) |
|
4.1 Neuronal dysfunction following cardiac arrest and cardiopulmonary resuscitation |
|
|
325 | (2) |
|
4.2 Neuroprotective effects of methylene blue |
|
|
327 | (2) |
|
5 Our investigations on cardiac arrest and reperfusion induced brain pathology |
|
|
329 | (2) |
|
5.1 Methodological consideration |
|
|
329 | (2) |
|
6 Brain pathology in cardiac arrest |
|
|
331 | (3) |
|
|
331 | (1) |
|
|
332 | (1) |
|
6.3 Albumin immunohistochemistry |
|
|
332 | (1) |
|
6.4 Glial fibrillary acidic protein (GFAP) immunohistochemistry |
|
|
332 | (1) |
|
6.5 Hemeoxygenase (HO) HO-1 and HO-2 immunochemistry |
|
|
332 | (1) |
|
6.6 Semiquantitative analysis of images |
|
|
332 | (1) |
|
6.7 Transmission electron microscopy |
|
|
333 | (1) |
|
|
333 | (1) |
|
6.9 Hemeoxygenase HO-1 and HO-2 ELISA |
|
|
333 | (1) |
|
|
333 | (1) |
|
6.11 Statistical analysis of the data |
|
|
334 | (1) |
|
|
334 | (12) |
|
7.1 Cardiac arrest and blood-brain barrier permeability |
|
|
334 | (1) |
|
7.2 Cardiac arrest and brain edema formation |
|
|
334 | (2) |
|
7.3 Cardiac arrest and HO-1 and HO-2 biochemistry |
|
|
336 | (3) |
|
|
339 | (1) |
|
|
339 | (1) |
|
|
339 | (1) |
|
7.7 HO-1 and HO-2 immunoreactivity |
|
|
339 | (3) |
|
|
342 | (1) |
|
7.9 Methylene blue treatment induces neuroprotection |
|
|
342 | (4) |
|
|
346 | (31) |
|
|
349 | (1) |
|
|
350 | (1) |
|
|
350 | (27) |
|
Chapter 8 Multimodal imaging in the differential diagnosis of glioma recurrence from treatment-related effects: A protocol for systematic review and network meta-analysis |
|
|
377 | (8) |
|
|
|
|
|
|
|
|
|
|
|
378 | (1) |
|
|
379 | (2) |
|
|
379 | (1) |
|
2.2 Selection of studies and data collection process |
|
|
379 | (1) |
|
|
380 | (1) |
|
2.4 Geometry of the network |
|
|
381 | (1) |
|
|
381 | (1) |
|
3 Protocol and registration |
|
|
381 | (1) |
|
|
381 | (4) |
|
|
382 | (1) |
|
|
382 | (3) |
|
Chapter 9 Manganese nanoparticles induce blood-brain barrier disruption, cerebral blood flow reduction, edema formation and brain pathology associated with cognitive and motor dysfunctions |
|
|
385 | (22) |
|
|
|
|
|
|
|
|
|
|
|
|
|
386 | (1) |
|
|
387 | (2) |
|
|
387 | (1) |
|
2.2 Exposure to manganese nanoparticles |
|
|
387 | (1) |
|
2.3 Blood-brain barrier permeability |
|
|
388 | (1) |
|
|
388 | (1) |
|
2.5 Brain edema formation and volume swelling |
|
|
388 | (1) |
|
2.6 Sensory motor functions |
|
|
388 | (1) |
|
2.7 Morphological analyses |
|
|
389 | (1) |
|
2.8 Statistical analyses of the data |
|
|
389 | (1) |
|
|
389 | (9) |
|
3.1 Effect of MnO2 nanoparticles on blood-brain barrier permeability |
|
|
389 | (1) |
|
3.2 Effect of MnO2 nanoparticles on cerebral blood flow |
|
|
390 | (1) |
|
3.3 Effect of MnO2 nanoparticles on brain edema formation and volume swelling |
|
|
390 | (3) |
|
3.4 Effect of MnO2 nanoparticles on neuronal injury |
|
|
393 | (2) |
|
3.5 Effect of MnO2 nanoparticles on sensory motor functions |
|
|
395 | (3) |
|
|
398 | (9) |
|
|
399 | (1) |
|
|
400 | (1) |
|
|
400 | (7) |
|
Chapter 10 Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient |
|
|
407 | |
|
|
|
|
|
|
|
|
408 | (1) |
|
|
408 | (2) |
|
|
410 | (2) |
|
|
412 | |
|
|
413 | |